Glenmede Trust Co. NA Grows Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Glenmede Trust Co. NA lifted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,512 shares of the medical instruments supplier’s stock after purchasing an additional 136 shares during the quarter. Glenmede Trust Co. NA’s holdings in LeMaitre Vascular were worth $976,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Driehaus Capital Management LLC increased its stake in LeMaitre Vascular by 52.2% in the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after acquiring an additional 90,573 shares during the last quarter. F M Investments LLC bought a new position in shares of LeMaitre Vascular in the second quarter worth approximately $7,443,000. Nicholas Investment Partners LP purchased a new stake in LeMaitre Vascular in the second quarter valued at approximately $3,900,000. Conestoga Capital Advisors LLC lifted its position in LeMaitre Vascular by 1.9% during the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock valued at $183,769,000 after purchasing an additional 36,850 shares during the last quarter. Finally, Rice Hall James & Associates LLC grew its stake in LeMaitre Vascular by 15.7% in the 3rd quarter. Rice Hall James & Associates LLC now owns 261,306 shares of the medical instruments supplier’s stock worth $24,273,000 after buying an additional 35,383 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $105.47 on Tuesday. LeMaitre Vascular, Inc. has a fifty-two week low of $52.55 and a fifty-two week high of $109.58. The firm has a market cap of $2.37 billion, a PE ratio of 57.63, a price-to-earnings-growth ratio of 2.62 and a beta of 0.89. The business has a 50 day moving average price of $95.80 and a 200-day moving average price of $88.23.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company’s revenue was up 15.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.33 EPS. Research analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.61%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s payout ratio is 34.97%.

Wall Street Analyst Weigh In

LMAT has been the subject of a number of research analyst reports. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective for the company. JMP Securities lifted their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 20th. Barrington Research increased their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, Oppenheimer reiterated an “outperform” rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, LeMaitre Vascular has an average rating of “Moderate Buy” and an average target price of $94.57.

Insiders Place Their Bets

In related news, Director Bridget A. Ross sold 3,750 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the transaction, the director now owns 2,278 shares in the company, valued at $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 10.79% of the company’s stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.